• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Research and Markets: Hot Drinks: Global Industry Almanac

    Research and Markets: Hot Drinks: Global Industry Almanac

  2. Research and Markets: OTC Pharmaceuticals: Global Industry Guide 2014-2018: Market to value $170,812.0m by the end of 2018

    Research and Markets: OTC Pharmaceuticals: Global Industry Guide 2014-2018: Market to value $170,812.0m by the end of 2018

  3. Novartis Upbeat Despite Weaker Profit -- Update

    Novartis Upbeat Despite Weaker Profit -- Update

  4. Research and Markets: APAC Epilepsy Therapeutics Market 2015-2019 with Eisai, GlaxoSmithKline , Pfizer & UCB Dominating

    Research and Markets: APAC Epilepsy Therapeutics Market 2015-2019 with Eisai, GlaxoSmithKline , Pfizer & UCB Dominating

  5. CORRECTING and REPLACING Pernix Therapeutics Exceeds 2014 Revenue Guidance: Delivers FY2014 Net Revenue In Excess of $120 Million

    CORRECTING and REPLACING Pernix Therapeutics Exceeds 2014 Revenue Guidance: Delivers FY2014 Net Revenue In Excess of $120 Million

  6. Research and Markets: Lung Cancer Clinical Trial Overview 2014

    Research and Markets: Lung Cancer Clinical Trial Overview 2014

  7. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

  8. Research and Markets: Global CINV Existing and Pipeline Drugs (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) Market 2014 - 2020

    Research and Markets: Global CINV Existing and Pipeline Drugs (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) Market 2014 - 2020

  9. Reformulation of Marketed Drugs Expected to Boost the Epilepsy Market in the US by 2019: TechNavio

    Reformulation of Marketed Drugs Expected to Boost the Epilepsy Market in the US by 2019: TechNavio

  10. Pernix Therapeutics Announces FDA Acceptance With Priority Review of Its TREXIMET® sNDA for Use in Adolescent Patients

    Pernix Therapeutics Announces FDA Acceptance With Priority Review of Its TREXIMET® sNDA for Use in Adolescent Patients

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.